Developer docs
API playgroundTry for free, no card

Search company profiles

Nephrosant

Full company profile

uuid0000pag

Namestring
Nephrosant
Websiteurl
nephrosant.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

NephroSant is a privately-held renal diagnostics company founded in 2017 in Brisbane, California, developing biomarker-based tools for early detection and lifetime monitoring of kidney health and injury, primarily serving clinical nephrology and dialysis customers.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
kidney disease diagnostics, nephrology diagnostic tools, urinary biomarker testing, renal injury monitoring, kidney health detection
Industry1 code
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Kidney Diagnostics
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nephrosant develops and delivers diagnostic tools for the early detection and lifetime monitoring of kidney health and injury. The company focuses on biomarker-based testing approaches aimed at identifying kidney damage earlier than conventional methods, enabling clinicians to track renal function over time.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Kidney Health Diagnostic Tool
CategoryKidney Diagnostics
Description

A diagnostic tool for early detection and lifetime monitoring of kidney health and injury, intended for clinical use by healthcare providers and nephrology specialists.

No data
Peers10 records
TypeBroad incumbent
Description

Bio-Techne supplies kidney-injury biomarker reagents (e.g., NGAL, KIM-1) and diagnostic tools to research and clinical labs, making it a broad incumbent in the renal biomarker/diagnostic supply chain that NephroSant competes against or partners with.

TypeOthers
Description

Eurofins operates a global network of clinical diagnostic laboratories, including specialty biomarker testing, and could serve as a contract lab partner or competitor for NephroSant's kidney diagnostic tests.

3ChemoCentryx (Amgen)
TypeBroad incumbent
Description

Amgen's acquisition of ChemoCentryx brought Tavneos, approved for ANCA-associated vasculitis (a kidney-relevant disease), illustrating the strategic value of nephrology assets; Amgen also operates in CKD therapeutics and is a comparable broad incumbent in kidney care.

TypeEmerging player
Description

ProKidney is a clinical-stage cell-therapy company focused on CKD/diabetic kidney disease, representing an adjacent emerging player in the kidney disease therapeutic/diagnostic space that targets the same patient population.

TypeBroad incumbent
Description

Quest Diagnostics is a major clinical reference lab offering kidney function testing (eGFR, microalbumin, cystatin C) and is a primary incumbent whose standard kidney panels NephroSant's novel biomarkers would need to displace or complement.

TypeBroad incumbent
Description

DaVita is the largest US dialysis provider and a strategic investor in NephroSant; it represents both the primary commercial channel opportunity and a broad incumbent in kidney care that could internalize or substitute competing diagnostics.

TypeBroad incumbent
Description

Fresenius is the world's largest dialysis services and products provider with growing interest in CKD diagnostics and home monitoring, providing a comparable incumbent channel and competitive threat to NephroSant's kidney monitoring business.

TypeDirect peer
Description

EKF Diagnostics develops point-of-care clinical chemistry analyzers (including kidney-related markers like creatinine and eGFR) and aims at rapid kidney health diagnostics, comparable in customer channel (clinics/labs) and renal testing focus.

TypeDirect peer
Description

Natera offers Renasight, a hereditary kidney disease genetic test, and broader organ-health biomarker diagnostics, overlapping with NephroSant's kidney diagnostic testing focus and clinical-channel distribution model.

TypeDirect peer
Description

Renalytix AI built a biomarker-based diagnostic (KidneyIntelX) for early-stage diabetic kidney disease risk assessment, directly comparable to NephroSant's early-detection kidney diagnostic mission in target customer and clinical use case.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nephrosant

Kidney Diagnosticsnephrosant.com

NephroSant is a privately-held renal diagnostics company founded in 2017 in Brisbane, California, developing biomarker-based tools for early detection and lifetime monitoring of kidney health and injury, primarily serving clinical nephrology and dialysis customers.

Nephrosant firmographics

Firmographics
Name
Nephrosant
Website
https://nephrosant.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Short description
NephroSant is a privately-held renal diagnostics company founded in 2017 in Brisbane, California, developing biomarker-based tools for early detection and lifetime monitoring of kidney health and injury, primarily serving clinical nephrology and dialysis customers.
Ownership category
akta.pro rank

Nephrosant industry classification

Industry
Product category
Kidney Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)

Keywords

  • Kidney disease diagnostics
  • Nephrology diagnostic tools
  • Urinary biomarker testing
  • Renal injury monitoring
  • Kidney health detection

Where Nephrosant is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Markets served

Nephrosant business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Nephrosant product offering

Product offering

Core offering

Nephrosant develops and delivers diagnostic tools for the early detection and lifetime monitoring of kidney health and injury. The company focuses on biomarker-based testing approaches aimed at identifying kidney damage earlier than conventional methods, enabling clinicians to track renal function over time.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kidney Health Diagnostic Tool A diagnostic tool for early detection and lifetime monitoring of kidney health and injury, intended for clinical use by healthcare providers and nephrology specialists.

Companies that use Nephrosant

Customer profile

Ideal customer profiles2 records

Nephrosant technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nephrosant competitors and assessment

Company assessment

Broad incumbents

  • Bio-Techne: Bio-Techne supplies kidney-injury biomarker reagents (e.g., NGAL, KIM-1) and diagnostic tools to research and clinical labs, making it a broad incumbent in the renal biomarker/diagnostic supply chain that NephroSant competes against or partners with.
  • ChemoCentryx (Amgen): Amgen's acquisition of ChemoCentryx brought Tavneos, approved for ANCA-associated vasculitis (a kidney-relevant disease), illustrating the strategic value of nephrology assets; Amgen also operates in CKD therapeutics and is a comparable broad incumbent in kidney care.
  • Quest Diagnostics: Quest Diagnostics is a major clinical reference lab offering kidney function testing (eGFR, microalbumin, cystatin C) and is a primary incumbent whose standard kidney panels NephroSant's novel biomarkers would need to displace or complement.
  • DaVita: DaVita is the largest US dialysis provider and a strategic investor in NephroSant; it represents both the primary commercial channel opportunity and a broad incumbent in kidney care that could internalize or substitute competing diagnostics.
  • Fresenius Medical Care: Fresenius is the world's largest dialysis services and products provider with growing interest in CKD diagnostics and home monitoring, providing a comparable incumbent channel and competitive threat to NephroSant's kidney monitoring business.

Others

  • Eurofins Scientific: Eurofins operates a global network of clinical diagnostic laboratories, including specialty biomarker testing, and could serve as a contract lab partner or competitor for NephroSant's kidney diagnostic tests.

Emerging players

  • ProKidney: ProKidney is a clinical-stage cell-therapy company focused on CKD/diabetic kidney disease, representing an adjacent emerging player in the kidney disease therapeutic/diagnostic space that targets the same patient population.

Direct peers

  • EKF Diagnostics: EKF Diagnostics develops point-of-care clinical chemistry analyzers (including kidney-related markers like creatinine and eGFR) and aims at rapid kidney health diagnostics, comparable in customer channel (clinics/labs) and renal testing focus.
  • Natera: Natera offers Renasight, a hereditary kidney disease genetic test, and broader organ-health biomarker diagnostics, overlapping with NephroSant's kidney diagnostic testing focus and clinical-channel distribution model.
  • Renalytix (Verici Dx): Renalytix AI built a biomarker-based diagnostic (KidneyIntelX) for early-stage diabetic kidney disease risk assessment, directly comparable to NephroSant's early-detection kidney diagnostic mission in target customer and clinical use case.

Market position

Customer concentration

Nephrosant social profiles

Digital presence

Nephrosant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nephrosant leadership team

Management profile

Number of profiles

Profiles5 records

Nephrosant funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nephrosant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nephrosant

What does Nephrosant do?

Nephrosant develops and delivers diagnostic tools for the early detection and lifetime monitoring of kidney health and injury. The company focuses on biomarker-based testing approaches aimed at identifying kidney damage earlier than conventional methods, enabling clinicians to track renal function over time.

When was Nephrosant founded?

Nephrosant was founded in 2017. It employs 1 to 10 people.

Where is Nephrosant based?

Nephrosant is headquartered in San Mateo, United States, in the North America region.

Who are Nephrosant's main competitors?

Broad incumbents on record are Bio-Techne, ChemoCentryx (Amgen), Quest Diagnostics, DaVita and Fresenius Medical Care. Eurofins Scientific is listed as an others. ProKidney is listed as an emerging player. Direct peers are EKF Diagnostics, Natera and Renalytix (Verici Dx).

Does Nephrosant have an API?

No public API is recorded for Nephrosant.

What industry is Nephrosant in?

Nephrosant's product category is Kidney Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNephroSant Launches Two-Year Study of 2,000 Kidney Transplant RecipientsNephroSant, Inc. has enrolled its first patient in the two-year AQUA study, which aims to assess the performance of its QSant diagnostic test in monitoring kidney transplant rejection among 2,000 recipients. The study will track participants for 24 months to compare QSant's ability to detect acute rejection against standard-of-care diagnostics. NephroSant expects the results to provide quantitative evidence that the test reduces rejection risk and reliance on invasive biopsies.PR NewswireNephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSantNephroSant announced that the Journal of Clinical Medicine published real-world evidence from a study of 235 patients at 11 U.S. transplant centers demonstrating that their QSant urine-based diagnostic test can effectively detect kidney transplant rejection risk across defined score ranges. The study showed scores below 32 indicate stable immune quiescence, scores between 32-55 signal alloimmunity flux with progression or resolution indicators, and scores above 55 correlate with acute rejection. The test, now covered by Medicare under a CMS local coverage determination, offers a non-invasive alternative to invasive biopsies for monitoring transplant patients.PR NewswireNephroSant Features QSant, the first urine test for kidney transplant rejection, at Biotech Showcase Digital 2022NephroSant, Inc., a biotechnology company dedicated to kidney health diagnostics, announced it will present at the Biotech Showcase conference (January 10-13 and 17-19, 2022) featuring QSant, the first entirely non-invasive urine test for early detection of kidney transplant rejection risk without requiring an invasive biopsy. QSant delivers accurate quantification of kidney transplant rejection risk from a non-timed urine sample collectable at home, and is fully reimbursed by Medicare for eligible transplant recipients when ordered by a healthcare professional. The company highlighted that clinical validation was published in Science Translational Medicine and the test has been studied through their Early Access Program across 11 transplant centers in the US.Daily Medical NewsCMS issues Medicare coverage to home-based kidney transplant rejection test by NephroSantCMS issued a local coverage determination for NephroSant's QSant, a needle-free urine test for kidney transplant rejection. The decision covers Medicare costs for eligible recipients, and the company plans to introduce the at-home test in coming months.PR NewswireNephroSant Secures Medicare Coverage for QSant, the First Urine-based Kidney Transplant Rejection Test, and Plans 2022 LaunchNephroSant announced that the Centers for Medicare & Medicaid Services (CMS) issued a local coverage determination for QSant, the first urine-based test for detecting kidney transplant rejection risk. This approval enables NephroSant to launch the non-invasive diagnostic tool, which uses AI to analyze urine biomarkers and provide a personalized rejection risk score to physicians. The company plans to introduce the test to patients in the coming months, allowing for proactive adjustment of immunosuppression therapy.PR NewswireNephroSant hires Gina Ford as CCO to lead global commercialization strategyNephroSant, a kidney health startup spun out of UCSF, has hired Gina Ford as Chief Commercial Officer to lead global commercialization of QSant, the first and only urine-based kidney rejection test. Ford brings 20 years of life sciences and pharmaceutical industry experience from prior roles at companies including Crinetics Pharmaceuticals, AcelRx, and Ipsen. The appointment is part of NephroSant's strategy to scale operations following a recent funding round and bring its diagnostic product to market.Poetsandquants2021 Best & Brightest MBAs: Joshua Yang, Stanford GSBJoshua Yang, a Stanford GSB MBA graduate, co-founded Nephrosant, a kidney disease diagnostics startup, and will launch Glyphic Biotechnologies as CEO after graduation. He raised $5M in seed funding during his second year. He also served as president of the GSB Pride Club and holds an MD-PhD in biomedical engineering.Daily Medical NewsNew surveillance tests can improve survival of donated kidneysNew non-invasive tests can detect early kidney graft rejection, potentially improving long-term survival. A study of 1,500 patients using CareDx's AlloSure test is underway, with results expected by 2022. Congress passed a bill to provide lifetime immunosuppressive drug coverage for kidney transplant patients.PR NewswireNephroSant Announces Mark Capone as Independent Board MemberNephroSant, a kidney health spin-out from UCSF, announced that Mark Capone has joined its Board of Directors, expanding the board to 7 directors with 2 independent members. Capone previously served as President and CEO of Myriad Genetics for 17 years, transforming it into a precision medicine company with over $800 million in annual revenues. The company aims to commercialize its first commercial test, QSant, for monitoring kidney allograft rejection, with plans to develop additional centralized and point-of-care tests for kidney diseases.